These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 7806367)

  • 21. Independent and synergistic effect of interleukin-2 and prolactin on development of T- and NK-derived LAK effectors.
    Cesano A; Oberholtzer E; Contarini M; Geuna M; Bellone G; Matera L
    Immunopharmacology; 1994; 28(1):67-75. PubMed ID: 7928303
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Distinct phenotypic and functional characteristics of human natural killer cells obtained by rapid interleukin 2-induced adherence to plastic.
    Vujanovic NL; Rabinowich H; Lee YJ; Jost L; Herberman RB; Whiteside TL
    Cell Immunol; 1993 Oct; 151(1):133-57. PubMed ID: 8402925
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Isolation of human NK cells and generation of LAK activity.
    Whiteside TL
    Curr Protoc Immunol; 2001 May; Chapter 7():Unit 7.7. PubMed ID: 18432847
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The presence and cytotoxicity of CD16+ CD2- subset from PBL and NK cells in long-term IL-2 cultures enhanced by Prothymosin-alpha.
    Cordero OJ; Sarandeses C; López-Rodríguez JL; Nogueira M
    Immunopharmacology; 1995 Apr; 29(3):215-23. PubMed ID: 7542644
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of human NK cell and LAK cell cytotoxicity and differentiation by PGE2.
    Leung KH
    Cell Immunol; 1989 Oct; 123(2):384-95. PubMed ID: 2507171
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Swainsonine, a glycosylation inhibitor, enhances both lymphocyte efficacy and tumour susceptibility in LAK and NK cytotoxicity.
    Galustian C; Foulds S; Dye JF; Guillou PJ
    Immunopharmacology; 1994; 27(2):165-72. PubMed ID: 7516929
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction of lymphokine-activated killer cells with low-dose interleukin 2 and interferon-gamma in oral cancer patients.
    Yoneda K; Yamamoto T; Ueta E; Osaki T
    J Clin Immunol; 1992 Jul; 12(4):289-99. PubMed ID: 1512302
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vivo boosting of lung natural killer and lymphokine-activated killer cell activity by interleukin-2: comparison of systemic, intrapleural and inhalation routes.
    Flexman JP; Manning LS; Robinson BW
    Clin Exp Immunol; 1990 Oct; 82(1):151-6. PubMed ID: 2208789
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antitumor activity, growth, and phenotype of long-term IL-2 cultures of human NK and T lymphocytes.
    Fuchshuber PR; Lotzová E; Pollock RE
    Lymphokine Cytokine Res; 1991 Apr; 10(1-2):51-9. PubMed ID: 1651770
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Surface characteristics, morphology, and ultrastructure of human adherent lymphokine-activated killer cells.
    Melder RJ; Walker ER; Herberman RB; Whiteside TL
    J Leukoc Biol; 1990 Aug; 48(2):163-73. PubMed ID: 1973444
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adherent lymphokine-activated killer cells suppress autologous human normal bone marrow progenitors.
    Miller JS; Verfaillie C; McGlave P
    Blood; 1991 Jun; 77(11):2389-95. PubMed ID: 1903991
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interferon-gamma-treated K562 target cells distinguish functional NK cells from lymphokine-activated killer (LAK) cells.
    Powell J; Stone J; Chan WC; Yang ZD; Leatherbury A; Sell KW; Wiktor-Jedrzejczak W; Ahmed-Ansari A
    Cell Immunol; 1989 Feb; 118(2):250-64. PubMed ID: 2491960
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD56bright natural killer cell subsets: characterization of distinct functional responses to interleukin-2 and the c-kit ligand.
    Carson WE; Fehniger TA; Caligiuri MA
    Eur J Immunol; 1997 Feb; 27(2):354-60. PubMed ID: 9045904
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Target cell-directed inactivation and IL-2-dependent reactivation of LAK cells.
    Xiao J; Brahmi Z
    Cell Immunol; 1989 Sep; 122(2):295-306. PubMed ID: 2788512
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interleukin-2 modulates the expression of lymphocyte function-associated antigen-one (LFA-1) and p150,95 during the generation of lymphokine-activated killer (LAK) cells.
    Grant AJ; Merchant RE; Hall RE
    Immunology; 1989 Jan; 66(1):117-24. PubMed ID: 15493273
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Phenotypical analysis of effector cells on nonspecific cancer cell therapy].
    Sudo T; Kobayashi Y; Matsushita N; Shimizu K; Nakao M; Tanaka Y; Tanigawa K; Aruga A
    Gan To Kagaku Ryoho; 2003 Oct; 30(11):1817-20. PubMed ID: 14619528
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunomagnetic isolation of NK and LAK cells.
    Naume B; Nonstad U; Steinkjer B; Funderud S; Smeland E; Espevik T
    J Immunol Methods; 1991 Jan; 136(1):1-9. PubMed ID: 1704900
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interleukin 2-activated killer cells in patients following transplants of soybean lectin-separated and E rosette-depleted bone marrow.
    Keever CA; Welte K; Small T; Levick J; Sullivan M; Hauch M; Evans RL; O'Reilly RJ
    Blood; 1987 Dec; 70(6):1893-903. PubMed ID: 3118990
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Resistance of chronic lymphocytic leukaemia cells to interferon-alpha generated lymphokine activated killer cells.
    Jewell AP; Worman CP; Giles FJ; Goldstone AH; Lydyard PM
    Leuk Lymphoma; 1992 Aug; 7(5-6):473-80. PubMed ID: 1362916
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhancement of MHC-unrestricted cytotoxic activity of human CD56+ CD3- natural killer (NK) cells and CD3+ T cells by rhamnogalacturonan: target cell specificity and activity against NK-insensitive targets.
    Zhu HG; Zollner TM; Klein-Franke A; Anderer FA
    J Cancer Res Clin Oncol; 1994; 120(7):383-8. PubMed ID: 7514604
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.